Unknown

Dataset Information

0

Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer.

ABSTRACT: Chemotherapy decreases the risk of relapse and mortality in early-stage breast cancer (BC), but it comes with the risk of toxicity. Chemotherapy efficacy depends on relative dose intensity (RDI), and an RDI?

SUBMITTER: Yuan Y 

PROVIDER: S-EPMC5576099 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer.

Yuan Yuan Y   Vora Nilesh N   Sun Can-Lan CL   Li Daneng D   Soto-Perez-de-Celis Enrique E   Mortimer Joanne J   Luu The-Hang TH   Somlo George G   Waisman James J   Smith David D   Chao Joseph J   Katheria Vani V   Synold Timothy T   Tran Vivi V   Mi Shu S   Levi Abrahm A   Arsenyan Anait A   Choi Jennifer J   Zavala Laura L   Yost Susan S   Hurria Arti A  

Breast cancer research : BCR 20170829 1

<h4>Background</h4>Chemotherapy decreases the risk of relapse and mortality in early-stage breast cancer (BC), but it comes with the risk of toxicity. Chemotherapy efficacy depends on relative dose intensity (RDI), and an RDI < 85% is associated with worse overall survival. The pro-inflammatory (interleukin (IL)-6, C-reactive protein (CRP)) and coagulation factors (D-dimer) serve as biomarkers of aging. The purpose of this study is to determine if these biomarkers are associated with reduced RDI  ...[more]

Similar Datasets

Unknown Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer.
| S-EPMC5634764 | biostudies-literature
Unknown The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
| S-EPMC5265784 | biostudies-literature
Unknown CYP2J2<sup>∗</sup>7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients.
| S-EPMC6527746 | biostudies-literature
Unknown Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia.
| S-EPMC5489802 | biostudies-literature
Unknown Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.
| S-EPMC6954126 | biostudies-literature
Unknown Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis.
| S-EPMC8417866 | biostudies-literature
Unknown FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma.
| S-EPMC8287268 | biostudies-literature
Unknown Ultrasound therapy with optimal intensity facilitates peripheral nerve regeneration in rats through suppression of pro-inflammatory and nerve growth inhibitor gene expression.
| S-EPMC7299378 | biostudies-literature
Unknown Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
| S-EPMC9255980 | biostudies-literature
Unknown Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials.
| S-EPMC6883296 | biostudies-literature